pf-08046054

Pancreatic Adenocarcinoma

Seagen, a wholly owned subsidiary of PfizerPhase 1Active

C

39/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 28/ 100
Competitive Position: 73/ 100

Competitive context

189 Active assets in the Pancreatic Adenocarcinoma cohort.

Asset / Sponsor	Phase	Rating
FLUOROURACILUM Jonsson Comprehensive Cancer Center	Phase 4	BBB
Docetaxel Bristol-Myers Squibb	Phase 2	BBB
Irinotecan Jonsson Comprehensive Cancer Center	Phase 3	BB
Eloxatin Jonsson Comprehensive Cancer Center	Phase 4	BB
Irinotecan Ipsen	Phase 3	BB

View all 50 →

Same molecule, other indications

pf-08046054 is also rated in:

non-small cell lung carcinomaDormant

B

Indicative ·

56 / 100

head and neck squamous cell carcinomaDormant

CC

Indicative ·

43 / 100

triple-negative breast carcinomaDormant

CC

Indicative ·

43 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.